Refers to a Pharmaceutical composition containing: (a) a protein iduronate-2-sulfatase (I2S) at a concentration of 1 mg \/ ml and comprising an amino acid sequence of sec id no: 1 (b) a Salt such as Sodium Chloride at a concentration of 0 to 300 mm (c) a Surfactant of polisorba To such as Polysorbate 20 at a concentration of 0 to 0.02% and (d) an agent such as phosphate buffer at a concentration of not more than 50 mm wherein the composition has a pH of 3 to 8 and is formulated as a liquid or powder dry powder. Said composition is administered intrathecally and is useful in the treatment of Syndrome of HuntersSE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) UNA PROTEINA IDURONATO-2-SULFATASA (I2S) A UNA CONCENTRACION DE 1 A 300 MG/ML Y COMPRENDE UNA SECUENCIA DE AMINOACIDOS DE SEC ID Nº: 1 B) UNA SAL TAL COMO CLORURO DE SODIO A UNA CONCENTRACION DE 0 A 300 mM C) UN TENSIOACTIVO DE POLISORBATO TAL COMO POLISORBATO 20 A UNA CONCENTRACION DE 0 A 0.02% Y D) UN AGENTE AMORTIGUADOR TAL COMO FOSFATO A UNA CONCENTRACION NO MAYOR DE 50 Mm EN DONDE LA COMPOSICION TIENE UN PH DE 3 A 8 Y ESTA FORMULADA COMO LIQUIDO O POLVO SECO LIOFILIZADO. DICHA COMPOSICION SE ADMINISTRA INTRATECALMENTE Y ES UTIL EN EL TRATAMIENTO DEL SINDROME DE HUNTERS
